Minimal Residual Disease Testing: Global Markets and Technologies

Aug 2023| PHM275A| BCC Publishing

Report Highlights

The global market for minimal residual disease testing is estimated to increase from $2.2 billion in 2023 to reach $4.3 billion by 2028, at a compound annual growth rate (CAGR) of 14.3% from 2023 through 2028.

Report Includes

  • 44 data tables and 45 additional tables
  • An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing
  • Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
  • Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
  • In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
  • Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
  • Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
  • Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
  • A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
  • Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
  • Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics

Report Scope

The report’s scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies’ mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

Frequently Asked Questions (FAQs)

The global minimal residual disease testing market was valued at $2.2 billion in 2023 and will reach $4.3 billion by 2028, at an estimated CAGR of 14.3%.
  • Rising incidence of cancer and hematological malignancies globally.
  • Advancements in Next Generation Sequencing (NGS) technology.
  • Growing awareness regarding early cancer detection.
The minimal residual disease testing market is segmented based on technology, application, and region.
Hematological malignancies segment will dominate the market by the end of 2028.
North America holds the highest share of the market.
Key companies in the market includes Exact Sciences Corp., Grail LLC, Natera, Inc., Invitae Corp., Qiagen N.V., and Quest Diagnostics among others.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $1.7 billion
Market size forecast $4.3 billion
Growth rate CAGR of 14.3% from 2023 to 2028
Units considered $ Millions
Segments covered By Technology, Application, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market Drivers
  • Rising Incidence of Cancer and Hematological Malignancies Globally
  • Advancements in Next Generation Sequencing (NGS) Technology
  • Increasing Awareness Regarding Early Cancer Detection
Companies studied
  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • AMGEN INC.
  • ASTRAZENECA
  • BIO-RAD LABORATORIES INC.
  • CERGENTIS B.V.
  • EXACT SCIENCES CORP.
  • GUARDANT HEALTH INC.
  • GRAIL LLC.
  • INVITAE
  • INVIVOSCRIBE INC.
  • NATERA INC.
  • NEOGENOMICS INC.
  • QIAGEN
  • SYSMEX CORP.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Minimal Residual Disease Testing: Global Markets and Technologies152Free
Chapter- 1: Introduction6Free
Chapter- 2: Summary and Highlights3Free
Chapter- 3: Market Overview5Free
Chapter- 4: Market Dynamics9Free
Chapter- 5: Global Minimal Residual Disease Testing Market by Technology8Free
Chapter- 6: Global Minimal Residual Disease Testing Market by Application19Free
Chapter- 7: Global Minimal Residual Disease Testing Market by Region21Free
Chapter- 8: ESG Developments8Free
Chapter- 9: Emerging Technologies and Developments1Free
Chapter- 10: M&A Analysis2Free
Chapter- 11: Competitive Intelligence12Free
Chapter- 12: Company Profiles58Free
Minimal Residual Disease Testing: Global Markets and Technologies

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS